CIK 0001807120 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Design Therapeutics, Inc.
Sign in to watch- Ticker
- DSGN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 823929248
- Phone
- 858-293-4900
- Business address
- 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD, CA, 92011
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- SC 13G Stake Amended Statement of Ownership
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- SC 13G Stake Amended Statement of Ownership
- SC 13D/A Stake Beneficial Ownership Report
- SC 13G Stake Amended Statement of Ownership
- 4 Open-market buy President and CEO bought 7,450 shares at an average $8.39 ($62,503)
- 4 Open-market buy Director bought 900,000 shares at an average $8.42 ($7,574,078)
- 4 Open-market buy 10% owner bought 900,000 shares at an average $8.42 ($7,574,078)
- 4 Open-market buy Director bought 15,000 shares at $7.96 ($119,426)
Page 8 of 14 · 268 filings